TherapeuticsMD, Inc.

Good morning, ladies and gentlemen. Thank you for joining us for the Therapeutics MD Third Quarter 2021 Financial Results Conference Call. Following prepared remarks from the company, we will open the call for questions. I would now like to turn the call over to Lisa Wilson, Investor Relations for Therapeutics MD. Lisa?

Thank you, Operator. Good morning, everyone, and thank you for joining today to discuss our third quarter financial results and business update. This morning, TherapeuticsMD issued a press release announcing our third quarter financial results. The press release and accompanying presentation are available on the company's website, therapeuticsmd.com, in the Investors and Media section. On today's call from TherapeuticsMD, our Chief Executive Officer, Rob Fenizio, President Hugh O'Dowd, Chief Financial Officer James Durecka, and Chief Commercial Officer Mark Glickman. I would like to remind everyone that certain statements made during this conference call may be forward-looking statements. Such forward-looking statements are based upon current expectations, and there can be no assurance that the results contemplated in these statements will be realized. Actual results may differ materially from such statements due to a number of factors and risks, some of which are identified in our press release and are annual, quarterly, and other reports filed with the SEC. These forward-looking statements are based on information available to TherapeuticsMD today, and the company assumes no obligation to update these statements as circumstances change. An audio recording and webcast replay for today's conference call will also be available online in the Investors and Media section of the company's website. For the benefit of those who may be listening to the replay or archive webcast, this call was held and recorded on November 11th, 2021. With that, I'll turn the call over to Therapeutics MD's CEO, Rob Fenizio.

Good morning, everyone, and thank you for joining our third quarter call. We look forward to updating you on the steady growth of our top-line sales, but before going into further detail, I have an important announcement to make. More than a year ago, I started a search for a company president who had the necessary financial and commercial expertise, the right personality, and the right strategic vision of someone who would eventually be my successor as the new CEO of TherapeuticsMD. Back in August, after a comprehensive and exhaustive search process, we hired Hugh O'Dowd to fill the role as our president. Hugh's a first-class professional with proven leadership and entrepreneurial skills, and deep industry knowledge, having held leadership positions at both large and small pharmaceutical companies. The Board of Directors and I have worked closely with Hugh since August to ensure he developed an in-depth understanding of Therapeutics MD. Now, I'm happy to announce that the Board of Directors have unanimously elected Hugh O'Dowd as Chief Executive Officer and member of the Board of Directors on or before the December 31st of 2021. After being at the helm of TherapeuticsMD since its inception 13 years ago, I will now transition to Vice Chairman of the Board of Directors and will now focus on board-level strategic direction of the company. I'm confident in usability to achieve our next milestone of even a break-even in the back half of 22 and building TherapeuticsMD into the premier women's health company in the United States. With that being said, I'd like to congratulate Hugh and ask Hugh to take over the call.